Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Authors
Keywords
-
Journal
Clinical Journal of the American Society of Nephrology
Volume -, Issue -, Pages CJN.02690320
Publisher
American Society of Nephrology (ASN)
Online
2020-06-10
DOI
10.2215/cjn.02690320
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
- (2020) Thomas A. Zelniker et al. CIRCULATION
- Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
- (2020) Clare Arnott et al. Journal of the American Heart Association
- Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
- (2019) Josef Coresh et al. Lancet Diabetes & Endocrinology
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- International Consensus on Risk Management of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Treated with Sodium-Glucose Cotransporter (SGLT) Inhibitors
- (2019) Thomas Danne et al. DIABETES CARE
- Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program
- (2019) Gemma A. Figtree et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
- (2019) Chintan V. Dave et al. ANNALS OF INTERNAL MEDICINE
- Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
- (2019) Toshiaki Ohkuma et al. Clinical Journal of the American Society of Nephrology
- SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis ‐ the STOP DKA Protocol
- (2019) Ronald M Goldenberg et al. DIABETES OBESITY & METABOLISM
- Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease
- (2019) Nisha Bansal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of AKI on Urinary Protein Excretion: Analysis of Two Prospective Cohorts
- (2019) Chi-yuan Hsu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus
- (2019) David D. Berg et al. CIRCULATION
- Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
- (2019) Michael A. Nauck et al. DIABETES CARE
- GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
- (2019) David Fitchett et al. EUROPEAN HEART JOURNAL
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study
- (2019) Nisha Bansal et al. CLINICAL CHEMISTRY
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study
- (2018) Digsu N. Koye et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
- (2018) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Metabolically Healthy Obesity and Risk of Kidney Function Decline
- (2018) Alex R. Chang et al. Obesity
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
- (2018) Katherine R Tuttle et al. Lancet Diabetes & Endocrinology
- Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
- (2018) Kristina S. Boye et al. Diabetes Therapy
- Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
- (2018) Kristina S. Boye et al. Diabetes Therapy
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- The Role of Deprescribing in Older Adults with Chronic Kidney Disease
- (2018) Laura K. Triantafylidis et al. DRUGS & AGING
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
- (2017) M. Monami et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor
- (2017) Jacob A. Udell et al. CIRCULATION
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
- (2016) Yoon-Kyung Chang et al. PLoS One
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Comorbidity as a driver of adverse outcomes in people with chronic kidney disease
- (2015) Marcello Tonelli et al. KIDNEY INTERNATIONAL
- Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes
- (2015) Vasilios Papademetriou et al. KIDNEY INTERNATIONAL
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- ESRD and Death after Heart Failure in CKD
- (2014) M. Sud et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Association of Clinical Symptomatic Hypoglycemia With Cardiovascular Events and Total Mortality in Type 2 Diabetes: A nationwide population-based study
- (2012) P.-F. Hsu et al. DIABETES CARE
- Acute Kidney Injury Episodes and Chronic Kidney Disease Risk in Diabetes Mellitus
- (2011) C. V. Thakar et al. Clinical Journal of the American Society of Nephrology
- A Predictive Model for Progression of Chronic Kidney Disease to Kidney Failure
- (2011) Navdeep Tangri JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Albuminuria and Estimated Glomerular Filtration Rate Independently Associate with Acute Kidney Injury
- (2010) M. E. Grams et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Severe Hypoglycemia and Risks of Vascular Events and Death
- (2010) Sophia Zoungas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
- (2009) M. F. Moen et al. Clinical Journal of the American Society of Nephrology
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started